Focused On-demand Library for Serine/threonine-protein kinase D1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Protein kinase C mu type; Protein kinase D; nPKC-D1; nPKC-mu

Alternative UPACC:

Q15139; A6NL64; B2RAF6


Serine/threonine-protein kinase D1, also known as Protein kinase C mu type, plays a pivotal role in various cellular processes. It converts transient diacylglycerol signals into prolonged physiological effects, influencing MAPK8/JNK1 and Ras signaling, Golgi membrane integrity, cell survival, migration, differentiation, proliferation, cardiac hypertrophy, angiogenesis, apoptosis, and inflammatory responses. This protein's ability to phosphorylate the epidermal growth factor receptor and regulate integrin recycling underscores its multifaceted role in cellular signaling pathways.

Therapeutic significance:

Given its involvement in congenital heart defects and ectodermal dysplasia, Serine/threonine-protein kinase D1 represents a promising target for therapeutic intervention. Understanding the role of this kinase could open doors to potential therapeutic strategies, offering hope for patients suffering from these complex conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.